

Key Topics Covered:

Part I: Lymphoma

5.1 The Scope of this Report

6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)

7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development (173 Drug Target Strategies and 282 Lymphoma Drugs)

8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy (8 Compound Strategies)

9 Selecting Subindication for Lymphoma Drugs (Five Subindications of Lymphoma)

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator (152 Companies)

11 Disclaimer

12 Drug Index

13 Company Index

Figures: Includes 6 Figures

Tables: Includes 222 Tables

Part II: Prostate Cancer

5.1 The Scope of this Report

6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets)

7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs)

8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies)

9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs)

10 Disclaimer

Figures: Includes 8 Figures

Tables: Includes 283 Tables

Part III: Apoptosis

5.1 The Scope of this Report

6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets)

7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs)

8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy (7 Compound Strategies)

9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications)

10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs)

Disclaimer

11 Drug Index

12 Company Index

Figures: Includes 7 Figures

Tables: Includes 315 Tables